Lenograstim
From Wikipedia, the free encyclopedia
Clinical data | |
---|---|
Trade names | Euprotin, Granocyte, Lenobio, Neutrogin |
AHFS/Drugs.com | International Drug Names |
Legal status | ? |
Identifiers | |
CAS number | 135968-09-1 |
ATC code | L03AA10 |
UNII | 6WS4C399GB |
Chemical data | |
Formula | ? |
(what is this?) (verify) | |
Lenograstim is a recombinant granulocyte colony-stimulating factor which functions as an immunostimulator.[1][2] It is developed by Chugai Pharmaceuticals under the brand name Granocyte.
References
- ↑ "USAN Council. List No. 340. New names. Lenograstim". Clin. Pharmacol. Ther. 52 (1): 113. July 1992. PMID 1284891.
- ↑ Amadori S, Suciu S, Jehn U, Stasi R, Thomas X, Marie JP, Muus P, Lefrère F, Berneman Z, Fillet G, Denzlinger C, Willemze R, Leoni P, Leone G, Casini M, Ricciuti F, Vignetti M, Beeldens F, Mandelli F, De Witte T (July 2005). "Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study". Blood 106 (1): 27–34. doi:10.1182/blood-2004-09-3728. PMC 1895135. PMID 15761020.
|
This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.